Current status of cardiac glycoside drug interactions.
The effects of concomitant drug therapy on the absorption, distribution, and elimination of digoxin and digitoxin are reviewed. A number of agents can increase or decrease the absorption of digoxin and digitoxin from the gastrointestinal tract by altering GI motility, binding the drugs through physical adsorption, altering the properties of the intestinal wall, or altering the bacterial flora of the intestine. The steady-state serum concentrations of digoxin and digitoxin can be affected if the changes in absorption are of sufficient magnitude, and adjustments in digoxin or digitoxin dosage may be required. A reduction in digoxin and digitoxin protein binding has occurred during concomitant administration of heparin and cardiac glycosides. Since digitoxin is more highly protein bound than digoxin, interactions that involve changes in protein binding are of much greater clinical importance with digitoxin. A number of drugs increase or decrease the elimination of digoxin and digitoxin, and subtherapeutic or toxic concentrations of the cardiac glycosides often result. Drugs that induce hepatic microsomal enzymes can increase the elimination of digitoxin, which is eliminated mainly by hepatic biotransformation. Digoxin is eliminated mainly by renal excretion; renal clearance of digoxin may be increased by vasodilators and thyroid hormones and decreased by quinidine, verapamil, amiodarone, and potassium-sparing diuretics. The clinical importance of changes in serum concentrations of the cardiac glycosides that result from alterations in glycoside elimination requires further study, as does the importance of preliminary reports of interactions between cardiac glycosides and diazepam, captopril, and combination therapy with quinidine-pentobarbital or quinidine-rifampin. Because the cardiac glycosides have a narrow therapeutic range, patients receiving concomitant therapy with agents that might affect the absorption, distribution, or elimination of the cardiac glycosides should be monitored carefully for symptoms of digitalis toxicity or undertreatment.
P M
PM
Hooymans
F W
FW
Merkus
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D013956:Antithyroid Agents / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002301:Cardiac Glycosides / Q000378:metabolism / Q000494:pharmacology*; D002927:Cimetidine / Q000494:pharmacology; D004074:Digitoxin / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000652:urine; D004077:Digoxin / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000652:urine; D004232:Diuretics / Q000494:pharmacology; D004347:Drug Interactions; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption; D011802:Quinidine / Q000494:pharmacology; D013963:Thyroid Hormones / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D000893:Anti-Inflammatory Agents; D013956:Antithyroid Agents; D002121:Calcium Channel Blockers; D002301:Cardiac Glycosides; D004232:Diuretics; D005765:Gastrointestinal Agents; D013963:Thyroid Hormones; D014665:Vasodilator Agents; D004077:Digoxin; D002927:Cimetidine; D006493:Heparin; D004074:Digitoxin; D011802:Quinidine